Mild hemophilia B

Mild hemophilia B, also known as mild Christmas disease or mild factor IX deficiency, is a genetic bleeding disorder caused by a partial deficiency of coagulation factor IX (FIX). It is classified as mild when factor IX activity levels are between 5% and 40% of normal. Factor IX is a critical protein in the intrinsic pathway of the blood coagulation cascade, and its deficiency impairs the body's ability to form stable blood clots. The condition primarily affects the hematologic system, though bleeding can occur in virtually any tissue or organ. Individuals with mild hemophilia B typically do not experience spontaneous bleeding episodes, which distinguishes them from those with moderate or severe forms. Instead, they tend to bleed excessively after trauma, surgery, or dental procedures. Symptoms may include prolonged bleeding from cuts, easy bruising, post-surgical hemorrhage, and occasionally prolonged bleeding after tooth extraction. Joint and muscle bleeds (hemarthrosis and intramuscular hematomas), which are hallmarks of severe hemophilia, are uncommon in the mild form. Because symptoms can be subtle, mild hemophilia B may not be diagnosed until later in life, often following an unexpected bleeding event during surgery or after an injury. Treatment focuses on preventing and managing bleeding episodes. The primary therapy involves replacement of factor IX, either through plasma-derived or recombinant factor IX concentrates, administered on-demand when bleeding occurs or prophylactically before surgical or dental procedures. Desmopressin (DDAVP), which is effective in some cases of mild hemophilia A, is not effective for hemophilia B. Antifibrinolytic agents such as tranexamic acid or aminocaproic acid may be used as adjunctive therapy, particularly for mucosal bleeding or dental procedures. With appropriate management, individuals with mild hemophilia B generally have an excellent prognosis and a normal life expectancy.

Common questions about Mild hemophilia B